Immunotherapy Emerges in Stage III NSCLC Treatment Landscape – OncLive
OncLiveImmunotherapy Emerges in Stage III NSCLC Treatment LandscapeOncLiveDo you think the success that we have seen with durvalumab is an indicator for upcoming immunotherapy agents in this stage? This is just the beginning. Most of my talk involved d… Continue reading
